|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCBP2 |
Gene summary for PCBP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCBP2 | Gene ID | 5094 |
| Gene name | poly(rC) binding protein 2 | |
| Gene Alias | HNRNPE2 | |
| Cytomap | 12q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q15366 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5094 | PCBP2 | CA_HPV_1 | Human | Cervix | CC | 3.13e-11 | -5.53e-02 | 0.0264 |
| 5094 | PCBP2 | CCI_1 | Human | Cervix | CC | 4.91e-02 | -4.02e-01 | 0.528 |
| 5094 | PCBP2 | CCI_3 | Human | Cervix | CC | 2.16e-04 | -5.07e-01 | 0.516 |
| 5094 | PCBP2 | CCII_1 | Human | Cervix | CC | 2.18e-07 | -5.20e-01 | 0.3249 |
| 5094 | PCBP2 | L1 | Human | Cervix | CC | 4.92e-02 | -2.73e-01 | 0.0802 |
| 5094 | PCBP2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.31e-03 | -1.91e-01 | 0.0155 |
| 5094 | PCBP2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.76e-06 | 4.27e-01 | -0.1954 |
| 5094 | PCBP2 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.96e-03 | 3.79e-01 | 0.096 |
| 5094 | PCBP2 | HTA11_6801_2000001011 | Human | Colorectum | SER | 4.16e-08 | 9.57e-01 | 0.0171 |
| 5094 | PCBP2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.96e-03 | 4.44e-01 | 0.0674 |
| 5094 | PCBP2 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.04e-11 | 1.53e+00 | 0.3487 |
| 5094 | PCBP2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.75e-15 | 9.27e-01 | 0.281 |
| 5094 | PCBP2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.59e-05 | 6.63e-01 | 0.3859 |
| 5094 | PCBP2 | A002-C-010 | Human | Colorectum | FAP | 7.37e-06 | -1.45e-01 | 0.242 |
| 5094 | PCBP2 | A015-C-203 | Human | Colorectum | FAP | 1.45e-26 | -3.02e-01 | -0.1294 |
| 5094 | PCBP2 | A015-C-204 | Human | Colorectum | FAP | 3.82e-04 | -1.73e-01 | -0.0228 |
| 5094 | PCBP2 | A014-C-040 | Human | Colorectum | FAP | 5.56e-03 | -1.80e-01 | -0.1184 |
| 5094 | PCBP2 | A002-C-201 | Human | Colorectum | FAP | 1.56e-10 | -1.94e-01 | 0.0324 |
| 5094 | PCBP2 | A001-C-119 | Human | Colorectum | FAP | 3.42e-03 | -2.94e-01 | -0.1557 |
| 5094 | PCBP2 | A001-C-108 | Human | Colorectum | FAP | 7.48e-17 | -3.43e-01 | -0.0272 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
| GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
| GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
| GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
| GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
| GO:001907910 | Cervix | CC | viral genome replication | 35/2311 | 131/18723 | 6.11e-06 | 1.49e-04 | 35 |
| GO:00028315 | Cervix | CC | regulation of response to biotic stimulus | 67/2311 | 327/18723 | 1.79e-05 | 3.36e-04 | 67 |
| GO:00096158 | Cervix | CC | response to virus | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
| GO:00028322 | Cervix | CC | negative regulation of response to biotic stimulus | 27/2311 | 108/18723 | 2.27e-04 | 2.55e-03 | 27 |
| GO:00507773 | Cervix | CC | negative regulation of immune response | 41/2311 | 194/18723 | 3.63e-04 | 3.76e-03 | 41 |
| GO:00321022 | Cervix | CC | negative regulation of response to external stimulus | 75/2311 | 420/18723 | 5.96e-04 | 5.61e-03 | 75 |
| GO:0031348 | Cervix | CC | negative regulation of defense response | 48/2311 | 258/18723 | 2.30e-03 | 1.65e-02 | 48 |
| GO:00190807 | Cervix | CC | viral gene expression | 21/2311 | 94/18723 | 4.68e-03 | 2.82e-02 | 21 |
| GO:00190817 | Cervix | CC | viral translation | 6/2311 | 16/18723 | 9.35e-03 | 4.66e-02 | 6 |
| GO:00516072 | Cervix | CC | defense response to virus | 46/2311 | 265/18723 | 1.04e-02 | 4.97e-02 | 46 |
| GO:01405462 | Cervix | CC | defense response to symbiont | 46/2311 | 265/18723 | 1.04e-02 | 4.97e-02 | 46 |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
| GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
| GO:0043161 | Colorectum | AD | proteasome-mediated ubiquitin-dependent protein catabolic process | 141/3918 | 412/18723 | 1.77e-10 | 1.68e-08 | 141 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0421614 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
| hsa0421615 | Cervix | CC | Ferroptosis | 14/1267 | 41/8465 | 1.75e-03 | 7.21e-03 | 4.26e-03 | 14 |
| hsa04216 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
| hsa042161 | Colorectum | AD | Ferroptosis | 21/2092 | 41/8465 | 2.23e-04 | 1.78e-03 | 1.13e-03 | 21 |
| hsa042162 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
| hsa042163 | Colorectum | MSS | Ferroptosis | 18/1875 | 41/8465 | 1.53e-03 | 8.53e-03 | 5.23e-03 | 18 |
| hsa042164 | Colorectum | FAP | Ferroptosis | 18/1404 | 41/8465 | 3.49e-05 | 3.65e-04 | 2.22e-04 | 18 |
| hsa042165 | Colorectum | FAP | Ferroptosis | 18/1404 | 41/8465 | 3.49e-05 | 3.65e-04 | 2.22e-04 | 18 |
| hsa042166 | Colorectum | CRC | Ferroptosis | 13/1091 | 41/8465 | 1.36e-03 | 1.08e-02 | 7.33e-03 | 13 |
| hsa042167 | Colorectum | CRC | Ferroptosis | 13/1091 | 41/8465 | 1.36e-03 | 1.08e-02 | 7.33e-03 | 13 |
| hsa0421616 | Endometrium | AEH | Ferroptosis | 15/1197 | 41/8465 | 2.83e-04 | 2.30e-03 | 1.68e-03 | 15 |
| hsa0421617 | Endometrium | AEH | Ferroptosis | 15/1197 | 41/8465 | 2.83e-04 | 2.30e-03 | 1.68e-03 | 15 |
| hsa0421625 | Endometrium | EEC | Ferroptosis | 16/1237 | 41/8465 | 1.09e-04 | 1.08e-03 | 8.08e-04 | 16 |
| hsa0421635 | Endometrium | EEC | Ferroptosis | 16/1237 | 41/8465 | 1.09e-04 | 1.08e-03 | 8.08e-04 | 16 |
| hsa0421628 | Esophagus | HGIN | Ferroptosis | 15/1383 | 41/8465 | 1.35e-03 | 1.26e-02 | 1.00e-02 | 15 |
| hsa04216111 | Esophagus | HGIN | Ferroptosis | 15/1383 | 41/8465 | 1.35e-03 | 1.26e-02 | 1.00e-02 | 15 |
| hsa0421629 | Esophagus | ESCC | Ferroptosis | 33/4205 | 41/8465 | 4.58e-05 | 1.99e-04 | 1.02e-04 | 33 |
| hsa0421638 | Esophagus | ESCC | Ferroptosis | 33/4205 | 41/8465 | 4.58e-05 | 1.99e-04 | 1.02e-04 | 33 |
| hsa042168 | Liver | NAFLD | Ferroptosis | 12/1043 | 41/8465 | 2.98e-03 | 2.96e-02 | 2.39e-02 | 12 |
| hsa0421611 | Liver | NAFLD | Ferroptosis | 12/1043 | 41/8465 | 2.98e-03 | 2.96e-02 | 2.39e-02 | 12 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCBP2 | SNV | Missense_Mutation | c.255N>G | p.Ser85Arg | p.S85R | Q15366 | protein_coding | tolerated(0.11) | benign(0.009) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| PCBP2 | SNV | Missense_Mutation | novel | c.284N>C | p.Arg95Thr | p.R95T | Q15366 | protein_coding | tolerated(0.08) | benign(0.01) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| PCBP2 | SNV | Missense_Mutation | c.58A>G | p.Met20Val | p.M20V | Q15366 | protein_coding | deleterious(0) | possibly_damaging(0.812) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PCBP2 | SNV | Missense_Mutation | c.388C>G | p.Gln130Glu | p.Q130E | Q15366 | protein_coding | deleterious(0.02) | benign(0.092) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| PCBP2 | insertion | Frame_Shift_Ins | novel | c.482_483insT | p.Gln161HisfsTer61 | p.Q161Hfs*61 | Q15366 | protein_coding | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | ||
| PCBP2 | insertion | Frame_Shift_Ins | novel | c.347_348insAGACT | p.Gly117AspfsTer64 | p.G117Dfs*64 | Q15366 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| PCBP2 | insertion | Nonsense_Mutation | novel | c.349_350insACTAGGAAGCTCCACTGA | p.Gly117delinsAspTerGluAlaProLeuArg | p.G117delinsD*EAPLR | Q15366 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| PCBP2 | insertion | Frame_Shift_Ins | rs776329515 | c.517_518insC | p.Lys176GlufsTer46 | p.K176Efs*46 | Q15366 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| PCBP2 | insertion | Frame_Shift_Ins | rs776329515 | c.517_518insC | p.Lys176GlufsTer46 | p.K176Efs*46 | Q15366 | protein_coding | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PCBP2 | SNV | Missense_Mutation | c.524C>T | p.Pro175Leu | p.P175L | Q15366 | protein_coding | deleterious(0.02) | benign(0.036) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |